Novel ligand for quantification of synaptic density in brain (SV2A) is produced by PharmaSynth AS
PharmaSynth AS is producing GMP certified BF3-Dm-UCB-J, a precursor for [11C]UCB-J, a selective radioligand for synaptic vesicle glycoprotein 2A (SV2A), as well as its reference standard.
For more information regarding the ligand activity and findings, please consult the publications:
Lower synaptic density is associated with depression severity and network alterations
Holmes, S. E. et.al., Nat Commun. 2019, vol 10, issue 1529.
Finnema, S. J. et.al., Sci Transl Med. 2016, vol 8, issue 348.
Nabulsi, N. B. et al., J Nucl Med. 2016, 57, 777-784.
Corresponding products in our portfolio:
For further information regarding technical specifications please contact Jukka Hiltunen at email@example.com or our chief chemist, Olavi Loog at firstname.lastname@example.org or by using the contact form on our webpage.